Drug intelligence / Profile preview

RMMR1

Development stage: Preclinical
Lead developer: Remedii
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides

Overview

RMMR1 is a preclinical peptide-drug conjugate (PDC) being developed by Remedii for the treatment of brain disorders. The candidate utilizes Remedii's proprietary Cell Penetrating Peptide (CPP) and Intracellular Drug Delivery Technology (IDDT) platform, which is engineered to transport therapeutic agents across the blood-brain barrier (BBB) and into target cells within the central nervous system. While the specific molecular target and drug payload have not been publicly disclosed, RMMR1 represents the application of Remedii's delivery technology to neurological indications.

Beyond the preview

Go deeper on RMMR1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RMMR1.

Explore the full profile